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Guanosine (GUO) is a guanine-based purine nucleoside with important trophic functions
and promising neuroprotective properties. Although the neuroprotective effects of GUO
have been corroborated in cellular models of Parkinson’s disease (PD), its efficacy as an
antiparkinsonian agent has not been fully explored in PD animal models. Accordingly,
we evaluated the effectiveness of GUO in reversing motor impairments in several
rodent movement disorder models, including catalepsy, tremor, and hemiparkinsonism.
Our results showed that orally administered GUO antagonized reserpine-mediated
catalepsy, reduced reserpine-induced tremulous jaw movements, and potentiated the
number of contralateral rotations induced by L-3,4-dihydroxyphenylalanine in unilaterally
6-hydroxidopamine-lesioned rats. In addition, at 5 and 7.5 mg/kg, GUO inhibited
L-DOPA-induced dyskinesia in rats chronically treated with a pro-dopaminergic agent.
Overall, we describe the therapeutic potential of GUO, which may be effective not only
for reversing parkinsonian motor impairments but also for reducing dyskinesia induced
by treatment for PD.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative condition of the central nervous system (CNS)
characterized by bradykinesia, tremor, and rigidity (Poewe and Mahlknecht, 2009). The disorder,
which is secondary to the loss of dopamine neurons in the substantia nigra, affects approximately
1% of the population over the age of 65 years (Meissner et al., 2011). Since the 1970s, the main
therapeutic approach has consisted of administrating L-3,4-dihydroxyphenylalanine (L-DOPA)
or other dopamine receptor agonists, aiming to reestablish normal function in the affected
dopaminergic signaling circuitry (Poewe, 2009). However, adverse effects appear with the long
consumption of dopaminergic drugs (Huot et al., 2013), among which dyskinesia -specifically
L-DOPA-induced dyskinesia (LID)- is one of most often reported and most likely to impede normal
life. Antiparkinsonian drugs are even classified clinically based on their probability of inducing
dyskinesia, and it has been shown that rotating these drugs can diminish the appearance of these
adverse motor effects. Nevertheless, novel agents are clearly needed to improve the management of
PD (Schapira et al., 2006).
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Over recent years, new drugs have been developed that
not only improve the clinical response to classical drugs
but that also alleviate undesired side effects. Among these,
purine-based drugs, specifically adenosine A2A receptor (A2AR)
antagonists, represent realistic and promising non-dopaminergic
treatment options (Schapira et al., 2006). The nucleoside
guanosine (GUO) is a guanine-based purine that crosses
the blood–brain barrier (Jiang et al., 2008) and induces
behavioral effects in rodents. GUO has been demonstrated
to exert anticonvulsive (Lara et al., 2001), antinociceptive
(Schmidt et al., 2010), anxiolytic-like (Almeida et al., 2017),
and antidepressant-like effects (Bettio et al., 2014). In
addition, it may have trophic and neuroprotective effects
in neural cells (Rathbone et al., 1999; Lanznaster et al.,
2016), possibly though adenosine receptors modulation
(Dal-Cim et al., 2013). Furthermore, GUO can modulate
glutamatergic transmission by stimulating its uptake through
transporters and increasing glutamine synthetase activity
and glutamate turnover, thereby reducing extracellular
glutamate levels and protecting from excitotoxicity (Molz
et al., 2011; Dal-Cim et al., 2016). Similarly, GUO-induced
neuroprotection in ischemia-like models has been shown to
promote the reduction of nitroxidative stress, prevent the
alteration of mitochondrial membrane potentials (Thomaz
et al., 2016), and control the inflammatory response. These
effects occur through inhibition of the transcription factor
NF-κB translocation to the nucleus (Dal-Cim et al., 2013), and
through the reduction of inflammatory cytokines (Hansel et al.,
2015).
The biochemical mechanisms responsible for
neurodegeneration in PD are oxidative stress, mitochondrial
damage, exacerbated inflammatory response, and glutamatergic
excitotoxicity (Dexter and Jenner, 2013). Given the effects
of GUO, its use offers a promising therapeutic approach.
Interestingly, metabolomic analysis in a PD transgenic mouse
model showed decreased GUO levels in the brains of adult
transgenic mice with concurrent motor symptoms (Chen
et al., 2015). Moreover, reduced striatal GUO levels have
been observed after reserpine treatment (Loeﬄer et al., 1998).
The administration of reserpine to rodents gives the classic
acute pharmacological model of PD by creating a transient
parkinsonian-like state (Duty and Jenner, 2011). Reserpine
inhibits vesicular monoamine transport in the CNS, leading to
monoamine depletion and motor impairments that resemble
PD (e.g., hypokinesia, catalepsy, and oral tremor) (Leão et al.,
2015).
In this study, we investigated the pharmacological use
of GUO in animal models with motor impairments that
resemble PD. Locomotor activity and the effects of GUO
were investigated in mice with reserpine-mediated catalepsy
and reserpine-induced tremulous jaw movements (TJMs).
Contralateral rotations induced by L-DOPA in unilaterally
6-OHDA-lesioned rats were also assessed. Finally, we tested the
effect of GUO in hemiparkinsonian rats on the development
of LID. We aimed to provide evidence in support of
GUO as a novel agent for improving the management
of PD.
MATERIALS AND METHODS
Animals
Male Swiss albino mice (30–50 g; from the animal facility of
the Federal University of Santa Catarina, Florianópolis, Brazil)
and Sprague–Dawley rats (240–250 g; Charles River Laboratories,
L’Arbresle, France) were used. Animals were housed in standard
cages with free access to food and water, and were maintained
under controlled standard conditions (12 h dark/light cycles
starting at 7:30 a.m., 22◦C temperature, and 66% humidity).
All manipulations were carried out between 0900 and 1600 h.
Procedures in this study were performed in accordance with
relevant guidance from the National Institute of Health Guide
for the Care and Use of Laboratory Animals (NIH Publications
no. 80-23), the Guide for the Care and Use of Laboratory
Animals (Clark et al., 1997), and European Union directives
(2010/63/EU). The ethics committees of the relevant institutions
(CEUA/UFSC and CEEA/UB) approved the protocol. Efforts
were made to minimize suffering and reduce the number of
animals used in the experiments.
Drugs
Reserpine (Sigma-Aldrich, St. Louis, MO, United States)
was dissolved in 0.1% acetic acid for subcutaneous (s.c.)
administration. GUO (Sigma-Aldrich) was dissolved in
saline (NaCl 0.9%) containing 0.5% methylcellulose for oral
(p.o.) administration. The 6-hydroxydopamine (6-OHDA;
Sigma–Aldrich) was dissolved in a saline solution containing
0.05% ascorbic acid. DL-serine 2-(2,3,4-trihydroxybenzyl)
hydrazide hydrochloride (benserazide; Sigma-Aldrich) and
3,4-Dihydroxy-L-phenylalanine (L-DOPA; Abcam Biochemicals,
Cambridge, United Kingdom) were dissolved in saline for
intraperitoneal (i.p.) administration.
Assessment of TJMs
Mice were administered reserpine (1 mg/kg, s.c.) or vehicle
(0.1% acetic acid solution) twice at an interval of 48 h. GUO
(3, 5, 7.5, or 10 mg/kg; p.o.) was administrated 20 min before
behavioral testing and 24 h after the last injection of reserpine
(Figure 1A). To quantify the occurrence of oral dyskinesia, mice
were placed individually in a glass cylinder (13 cm diameter)
and hand-operated counters were used to count TJM frequency.
Mirrors were placed under the floor and behind the back wall
of the cylinder to allow observation when the animal faced
away from the observer. TJMs were defined as rapid vertical
deflections of the lower jaw that resembled chewing, but were not
directed at any particular stimulus (Salamone et al., 1998). If TJM
occurred during a period of grooming, they were discounted. The
incidence of these oral movements was measured continuously
for 10 min.
Catalepsy Trial
After treatment with reserpine alone or reserpine plus GUO
(Figure 1A), catalepsy behavior was assessed by placing the
forepaws of mice on a horizontal bar (6 mm diameter) positioned
at 4.5 cm above the bench surface. The duration of catalepsy,
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FIGURE 1 | Effect of guanosine (GUO) on reserpine-induced motor disturbances in mice. (A) Treatment schedule depicting the administration regimen of reserpine
(1 mg/ml; s.c.), guanosine (GUO, 0, 3, 5, 7.5, 10 mg/kg, p.o.) and behavioral testing. (B) Spontaneous locomotor activity of mice treated with saline (control
mice = Ctrl), or GUO (3, 5, 7.5, or 10 mg/kg, p.o.) after reserpine administration (see A) was evaluated in the open-field test. The distance traveled (m) was measured
during 10 min. Results are presented as means + SEM (n = 9–10 animals). #P < 0.05 and ##P< 0.01 one-way ANOVA with Tukey’s post hoc test when compared to
5 and 7.5 mg/kg GUO (#), and to 0, 3, and 10 mg/kg GUO (##). (C) Reserpine-induced orofacial dyskinesia evaluated by tremulous jaw movements (TJMs) frequency
during 10 min. Results are presented as means + SEM (n = 6 animals). #P < 0.05, ##P < 0.01, and ###P = 0.001 one-way ANOVA with Tukey’s post hoc test when
compared to 5 mg/kg GUO (#), to 3 mg/kg GUO (##) and to 0 and 10 mg/kg GUO (###). ∗∗P < 0.01 one-way ANOVA with Dunnett’s post hoc test when compared
to vehicle-treated (0 mg/kg GUO) animals. (D) Reserpine-induced catalepsy in mice evaluated by the latency scape in the bar test. Results are presented as
means + SEM (n = 9 animals). ##P < 0.01 one-way ANOVA with Tukey’s post hoc test when compared 0 mg/kg GUO. ∗P < 0.05 and ∗∗P < 0.01 one-way ANOVA
with Dunnett’s post hoc test when compared to 0 mg/kg GUO.
which was defined as an immobile posture, was measured
while the animal kept both forepaws on the bar, with a cut-off
maximum of 180 s. Three trials were carried out and the results
were analyzed using the mean value of the three trials, as adapted
from Santos et al. (2013).
Spontaneous Locomotor Activity
The spontaneous locomotor activity of mice after reserpine
or reserpine plus GUO treatment was tested in the open-
field test. The apparatus consisted of an acrylic box measuring
45 cm× 45 cm× 45 cm, with each mouse placed in the center and
recorded for 10 min with a video camera system. The distance
traveled by each animal was analyzed using Bonther Activity
Monitoring software (Bonther, Co., Brazil).
The spontaneous locomotor activity of rats was tested in an
open-field Plexiglas R© arena box measuring 1 m × 1 m × 1 m.
Each rat was placed in the center and recorded for 5 min, as
described above.
Hemiparkinsonian Animal Model
Experimental hemiparkinsonism was induced in rats by
unilateral injection of 6-OHDA in the medial forebrain bundle,
as previously described (Fernández-Dueñas et al., 2015). Rats
were stereotaxically injected with 6-OHDA (8 µg of 6-OHDA
in 4 µL of saline containing 0.05% ascorbic acid) at anterior–
posterior (AP; −2.2 mm), medial–lateral (ML; −1.5 mm), and
dorsal–ventral (DV; −7.8 mm) locations with respect to the
bregma (Paxinos and Watson, 2007). To minimize damage to
noradrenergic neurons, rats were pretreated with desipramine
hydrochloride (10 mg/kg, i.p.) 20 min before surgery.
Three weeks later the extent of dopamine deafferentation
was checked by assessing the rotating behavioral response to
L-DOPA administration. In brief, rats were injected with L-DOPA
(50 mg/kg, i.p.) in the presence of benserazide hydrochloride
(25 mg/kg, i.p.), an inhibitor of DOPA decarboxylase that
minimizes peripheral metabolization of L-DOPA, and the
number of full contralateral turns were recorded during a 2 h
period. Dopamine deafferentation was considered successful in
animals made at least 200 net contralateral rotations.
Thereafter, animals were housed for 3 weeks before being used
in the behavioral analyses. GUO was administered orally in a
vehicle (0.5% methylcellulose and 2% DMSO) 40 min before
benserazide (25 mg/kg; i.p.). Subsequently, L-DOPA (6 mg/kg;
i.p.) was delivered after 20 min. The animals were then placed in
the rotametry chambers, as previously described (Hodgson et al.,
2009), and the number of contralateral rotations was recorded
over a 2 h period.
LIDs and Abnormal Involuntary
Movements Rating
L-DOPA-induced dyskinesia were triggered in hemiparkinsonian
rats by twice daily administration of L-DOPA (6 mg/kg, i.p.) plus
benserazide hydrochloride (15 mg/kg, i.p) for 22 consecutive
days. L-DOPA-induced abnormal involuntary movements
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(AIMs) were scored by a blinded experimenter following a
previously described rat dyskinesia scale (Winkler et al., 2002).
In brief, rats were injected with L-DOPA, placed in individual
transparent plastic cages, and observed every 20 min for 220 min.
Three AIM subtypes were monitored (i.e., axial, forelimb,
and orolingual) and their respective severity scored from 0
to 4, as previously described (Winkler et al., 2002). Enhanced
manifestations of otherwise normal behaviors, such as rearing,
sniffing, grooming, and gnawing, were not included. AIM ratings
were performed on treatment days 1, 7, 14, and 22 during the
chronic L-DOPA administration phase. We calculated integrated
AIM scores for each animal and behavioral session using the sum
of all three AIM subtypes. AIM was also expressed as an area
under the curve (AUC) analysis.
Data Analysis
Data are represented as means ± SEM. Comparisons among
experimental and control groups were performed by one-way
analysis of variance (ANOVA) followed by Dunnett’s post hoc test
when comparing GUO treatments or Tukey’s post hoc test when
comparing to internal control within the behavioral test, if any.
Statistical significance was accepted when P < 0.05.
RESULTS
GUO Modulation of Reserpine-Induced
Motor Disturbances
Reserpine administration to mice was performed to evaluate
the ability of GUO to counteract reserpine-mediated changes
(Figure 1A). We first determined the change in spontaneous
locomotor activity. While it was significantly reduced by
reserpine administration, acute GUO treatment (3, 5, 7.5, or
10 mg/kg, p.o.) was unable to reverse the change [F(4,43)= 0.2241,
P = 0.9234] (Figure 1B).
Next, we assessed the ability of GUO to reduce reserpine-
induced TJMs, a parameter known to ameliorate by
antiparkinsonian drugs (Collins-Praino et al., 2011). Reserpine-
administered animals did, indeed, show a significant increase
in TJMs that was partially blocked by GUO administration
(Figure 1C). One-way ANOVA revealed significant differences
between the GUO-treated reserpinized mice [F(4,23) = 5.603,
P = 0.0027], with a significant reduction in reserpine-mediated
TJMs observed at 7.5 mg/kg GUO (P < 0.01) (Figure 1C).
Interestingly, treatment with 10 mg/kg of GUO was unable to
preclude reserpine-induced TJMs, thus resulting in a U-shaped
dose-dependent GUO activity (Figure 1C).
Finally, reserpine-induced catalepsy was assessed as an
experimental model of akinesia and bradykinesia (Duty and
Jenner, 2011). Reserpine treatment induced a cataleptic state, as
measured by the latency time of mice to move forepaws from
the bar in the bar test, and acute GUO treatment significantly
attenuated this increase in latency time [F(4,40) = 3.518,
P = 0.0149] (Figure 1D). GUO induced significant reductions
in reserpine-mediated catalepsy at doses of 7.5 mg/kg (P < 0.01)
and 10 mg/kg (P < 0.05) (Figure 1D).
Overall, although GUO did not reverse reserpine-induced
locomotor activity depression, it did ameliorate TJM and
catalepsy symptoms in reserpinized mice. Therefore, we
considered that antiparkinsonian efficacy was shown in this
classical pharmacological animal model of acute PD.
Antiparkinsonian Effect of GUO in
6-OHDA-Lesioned Rats
After assessing the effects of GUO on reserpinized mice, we
evaluated its effectiveness in unilateral 6-OHDA-lesioned
rats, a classic animal model of experimental parkinsonism
based on toxin-mediated destruction of the dopaminergic
nigrostriatal pathway (Schwarting and Huston, 1996).
Accordingly, we evaluated the impact of acute GUO treatment
on spontaneous locomotor activity and contralateral rotation
in 6-OHDA-lesioned rats (Figure 2A). First, we assessed
spontaneous locomotor activity of control and hemiparkinsonian
animals. While in 6-OHDA-lesioned animals GUO did not have
any effect, in saline-lesioned mice the one-way ANOVA analysis
revealed a significant GUO-induced increase in spontaneous
locomotor activity at 3 mg/kg (P < 0.05) (Figure 2B). Overall,
GUO was unable to potentiate spontaneous locomotor activity
in 6-OHDA-lesioned rats.
In the hemiparkinsonian animal model, asymmetric motor
behavior is observed following dopaminergic treatment
(i.e., L-DOPA) because of unilateral dopamine depletion in the
nigrostriatal pathway (Duty and Jenner, 2011). Interestingly,
when using submaximal doses of L-DOPA, it is possible to
potentiate contralateral rotations with other pro-dopaminergic
drugs (e.g., A2AR antagonists) (for review, see Vallano et al.,
2011). Therefore, we determined whether GUO could promote
contralateral rotations in 6-OHDA-lesioned animals with
submaximal (6 mg/kg) L-DOPA dosing in hemiparkinsonian rats
(Figure. 2C). GUO administration alone, up to 10 mg/kg, did not
result in asymmetric turning behavior in 6-OHDA-lesioned rats
(data not shown). However, GUO did dose-dependently induce
contralateral turning behavior when administrated before the
subthreshold dose of L-DOPA (Figure 2C). One-way ANOVA
revealed significant differences between GUO treatments
[F(3,36) = 11.65, P < 0.001] (Figure 2C), with GUO inducing
significant contralateral rotations at 3 mg/kg (P < 0.05) and
10 mg/kg (P < 0.001) (Figure 2C). Overall, GUO enhanced
the effects of L-DOPA with a minimum efficacious oral dose of
3 mg/kg.
Antidyskinetic Effect of GUO in the LID
Rat Model
Chronic L-DOPA use in PD is associated with the development
of LIDs. Therefore, we assessed the potential antidyskinetic
activity of GUO after inducing LIDs in 6-OHDA-lesioned
rats through chronic L-DOPA administration and monitoring
for the emergence of AIMs over time (Figure 3A). AIM
severity significantly (P < 0.01) increased after 1 week of
L-DOPA treatment (Figure 3A, inset, day 7), thus LID increased
during the first 40 min L-DOPA post-injection and remaining
elevated for an additional 40 min (Figure 3A, day 7). After
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FIGURE 2 | Effect of guanosine (GUO) on hemiparkinsonian rats. (A) Treatment schedule depicting the 6-OHDA lesion, rotational test (see section “Materials and
Methods”) and the administration regimen of guanosine (GUO, 0, 1, 3, 10 mg/kg, p.o.) and behavioral testing. (B) Total distance traveled in the open-field test by
either saline- or 6-OHDA-lesioned rats administered with L-DOPA after GUO treatment (3 or 10 mg/kg, p.o.). The distance traveled (cm) was measured during 5 min.
Values correspond to the mean ± SEM (n = 12). ∗P < 0.05 one-way ANOVA with Dunnett’s post hoc test when compared to 0 mg/kg GUO. (C) GUO-mediated
potentiation of L-DOPA-induced contralateral rotations in 6-OHDA-lesioned rats. The number of contralateral rotations in 6-OHDA-lesioned rats orally administered
with vehicle or GUO (1, 3, or 10 mg/kg) was monitored during a 2 h period. The control group (Ctrl) was administered with L-DOPA (50 mg/kg, i.p.). Values
correspond to the mean ± SEM (n = 10). ###P < 0.001 one-way ANOVA with Tukey’s post hoc test when compared to 0, 1, 3, and 10 mg/kg GUO. ∗P < 0.05 and
∗∗∗P < 0.001 one-way ANOVA with Dunnett’s post hoc test when compared to 0 mg/kg GUO.
2 weeks of L-DOPA treatment, the increase in LID was higher
(P < 0.001) (Figure 3A, inset, day 14) and sustained in time
(i.e., 150 min) (Figure 3A, day 14). Finally, after 3 weeks of
L-DOPA administration a similar AIMs increase and sustained
LID incidences were observed (Figure 3A, day 22), thus reaching
a LID plateau. Interestingly, the observed time-course in our
LID animal model resembled the so-called peak-dose dyskinesia
in PD (Fahn, 2000). Thus, we showed that GUO treatment
produced a U-shaped dose-dependent antidyskinetic activity in
animals administered with L-DOPA for 3 weeks (Figure 3B).
One-way ANOVA revealed significant differences between
GUO treatments [F(5,47) = 11.65, P = 4.866] (Figure 3B),
with significantly maximal GUO-induced antidyskinetic activity
observed at 5 mg/kg (P < 0.001) and 7.5 mg/kg (P < 0.05)
(Figure 3B). Overall, GUO showed antidyskinetic activity in the
LID animal model.
DISCUSSION
Given that dopamine replacement is the first line therapy
in PD, treatment with L-DOPA or dopamine agonists
(i.e., ropinirole, pramipexole, apomorphine) is the mainstay
of clinical management (Poewe and Mahlknecht, 2009).
Unfortunately, while dopamine-targeted therapies properly
address PD-associated motor disturbances, they also
have considerable acute and chronic side effect, including
hallucinations, constipation, nausea, somnolence, on/off effects,
and dyskinesia (Eggert et al., 2008). In addition, these therapies
not only show a progressive decline in efficacy over time but
they also do not address common mood, postural instability,
or cognitive disturbances. Thus, approaches that indirectly
modulate dopaminergic neurotransmission have emerged as
potential alternatives to handle side effects associated with PD
therapy (Fox et al., 2008).
In this study, we have shown the effectiveness of GUO, a
naturally occurring guanine-based purine nucleoside, in three
rodent models of impaired movement: (1) the reserpine-induced
TJM and catalepsy model in mice, (2) the hemiparkinsonian
model of PD in rats, and (3) the LID model in rats. Although
GUO was unable to improve spontaneous locomotor activity
in reserpine-treated mice, it did ameliorate TJMs and catalepsy
in those mice. In addition, GUO potentiated L-DOPA-induced
contralateral rotations in unilaterally 6-OHDA-lesioned rats and
showed antidyskinetic efficacy in the LID model. Collectively,
these results support the hypothesis that GUO has potential use
in PD management, including for reducing dyskinesia when used
in combination with L-DOPA.
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FIGURE 3 | Effect of guanosine (GUO) on dyskinetic rats. (A) Development of
L-DOPA induced motor side effects (i.e., LIDs) following chronic (22 days)
L-DOPA (6 mg/kg) administration. AIMs score was measured during a
220-min session on days 1, 7, 14, and 22 immediately after the corresponding
daily L-DOPA injection. (B) LIDs attenuation in chronic (22 days) L-DOPA
(6 mg/kg) administered rats following GUO administration. The total AIMs
score AUC obtained over 220 min following co-administration of L-DOPA
(6 mg/kg) plus vehicle or GUO (1, 3, 5, 7.5, or 10 mg/kg) are presented as
mean score ± SEM (n = 6). ∗P < 0.05 and ∗∗∗P < 0.001 one-way ANOVA
with Dunnett’s post hoc test when compared to 0 mg/kg GUO.
Guanosine has been shown to exert neuroprotective effects
in cellular models of PD. For instance, dopaminergic neurons
differentiated from human SH-SY5Y neuroblastoma cells were
shown to be protected from 6-OHDA-induced toxicity by GUO
treatment (Giuliani et al., 2012). The protective effects of
GUO were also observed in C6 glioma cells (as a model of
astrocytes) when incubated with 6-OHDA (Giuliani et al., 2014).
Similarly, GUO neuroprotection has been evidenced against
other PD-related toxins, such as 1-methyl-4-phenylpyridinium
(MPP+). Of note, MPP+ is taken up by dopaminergic neurons
and accumulates in their mitochondria, where it inhibits complex
I of the electron transport chain and ultimately causes neuronal
cell death. In SH-SY5Y cells, GUO given after as long as 24 h
after MPP+ was able to reduce MPP+-induced caspase-3 activity
(Pettifer et al., 2007).
Despite in vitro evaluations, data from in vivo GUO treatment
in PD models are scarce. Chronic treatment with GUO (8 mg/kg
for 8 weeks) can significantly reduce bradykinesia in proteasome
inhibitor (PSI)-treated rats (Su et al., 2009), which is an
animal model for slow-onset PD (McNaught et al., 2004).
In addition, chronic GUO treatment reduced apoptotic cell
death, induced proliferation of neural progenitor/stem cells, and
increased the number of tyrosine hydroxylase-positive cells in
the substantia nigra in a PSI model of PD (Su et al., 2009).
However, the acute effect and efficacy of GUO in reversing motor
impairments in rodent models of movement disorders, including
catalepsy, tremor, and hemiparkinsonism, have not previously
been addressed.
Reserpine administration to rodents is a primary model
for assessing potential PD treatments. L-DOPA efficacy was
first reported in this model by observing that it improved
the reserpine-induced akinetic state (Carlsson et al., 1957).
Even though reserpine does not induce dopaminergic
neurodegeneration, the model produces key motor disturbances
consistent with those of PD; for example, mice show decreased
spontaneous locomotor activity, which correlates to hypokinesia
in PD. However, although reserpine-induced catalepsy and TJM
were fully reversed, GUO treatment had no effect on spontaneous
locomotor activity at the doses tested in this study.
Regarding the hemiparkinsonian rats, unilateral 6-OHDA
lesions did not reduce, and subsequent GUO treatment did
not increase, spontaneous locomotor activity. Conversely, GUO
administration before the subthreshold dose of L-DOPA induced,
in a dose-dependent manner, contralateral turning behavior that
indicates a pro-dopaminergic action (i.e., GUO enhanced the
effects of L-DOPA). Moreover, GUO exerted an antidyskinetic
effect in rats chronically treated with L-DOPA. Besides L-DOPA
beneficial effects, this long-term therapy leads to development
of adverse motor responses, named LID. LIDs, in particular,
are a great burden that affects 40–50% of PD patients who
undergo L-DOPA treatment for 4–6 years (Ahlskog and Muenter,
2001). Taken together, results from reserpinized mice and
hemiparkisonian rats demonstrated that GUO did not alter
spontaneous locomotor activity. Interestingly, GUO presented
antidyskinetic effect (reducing TJMs in mice and AIMs in the
LID model in rats), although it was not observed in the higher
dose tested (10 mg/kg). Thus, this surprising U-shaped dose-
response of GUO efficacy alleviating TJMs and LID will deserve
further investigation in the future. Yet, GUO effect on reserpine-
induced catalepsy in mice and potentiation of L-DOPA-induced
contralateral rotations in 6-OHDA-lesioned rats was observed in
all doses tested. Overall, our data provide evidence that GUO
treatment may not only improve the motor symptoms of PD but
may also have a potential efficacy on L-DOPA side effects. Thus,
the potential clinical importance of this finding is significant.
Importantly, we demonstrated the antiparkinsonian efficacy
of GUO in a series of PD rodent models, consistent with other
A2AR antagonists (Vallano et al., 2011). Indeed, istradefylline
(Jenner, 2005) has recently been licensed for use in Japan as an
adjuvant to L-DOPA treatment for reducing off-times produced
by dopaminergic drugs (Mizuno et al., 2010; Kondo and Mizuno,
2015; Müller, 2015). The molecular target of GUO has not
yet been fully characterized and no GUO receptor has been
identified, though some studies have suggested its existence
(Traversa et al., 2002; Volpini et al., 2011). Alternatively, it has
been proposed that GUO might function by altering adenosine
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receptor functioning (Dal-Cim et al., 2011, 2013; Ciruela, 2013;
Lanznaster et al., 2016). Hence, the antiparkinsonian efficacy
of GUO might in fact be related to A2AR function, thus its
relationship with A2AR blockade should be further investigated
as previously done while assessing similar non-dopaminergic
approaches to PD therapy (Kase et al., 2003; Coccurello et al.,
2004). Therefore, more experimental work is needed to elucidate
the mechanism by which GUO exerts its antiparkinsonian action.
In summary, we have shown the remarkable potential of GUO
to ameliorate parkinsonian symptoms in experimental animal
models of movement disorders. Subject to further development,
GUO is likely to become an excellent candidate for a clinical
proof-of-concept study for purinergic-based treatment in PD.
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